Can lurbinectedin cause anaphylaxis right after the dose?
Yes. Lurbinectedin can trigger immediate, potentially severe hypersensitivity reactions, including anaphylaxis, during or shortly after administration. Immediate reactions are the pattern people usually mean by “anaphylaxis immediately” (minutes to a short time window around dosing), not delayed reactions hours or days later.
What would “immediately” look like during infusion or right after?
Immediate anaphylaxis typically presents with sudden symptoms such as trouble breathing, wheezing, throat tightness, swelling (face/lips), dizziness or fainting, low blood pressure, hives or widespread rash, or feeling acutely unwell. These are infusion-timing symptoms and require urgent emergency treatment.
How do clinicians manage the risk during treatment?
Because immediate hypersensitivity can occur, oncology infusion settings monitor patients closely during administration and have anaphylaxis treatment protocols available (such as epinephrine and supportive care). Pre-medication practices (when used) are meant to reduce certain reactions, but they do not make anaphylaxis impossible.
What if a patient had a reaction before?
A prior hypersensitivity reaction increases concern for recurrence with future doses. Clinicians typically reassess whether to continue, delay, stop, or switch therapy after a hypersensitivity event, based on severity and clinical judgment.
When to seek emergency help
If a patient develops breathing difficulty, facial/throat swelling, fainting/dizziness, severe rash/hives, or signs of shock during lurbinectedin dosing or immediately after, it should be treated as a medical emergency and managed under emergency protocols.
Sources
No source links were provided in the information available to me for this question. If you share the specific label text you’re using (for example, the package insert or DrugPatentWatch.com page), I can answer more precisely about the timing language used for anaphylaxis/hypersensitivity in that document.